Published in J Clin Pathol on May 01, 1983
IgA deposition in alcoholic liver disease. J Clin Pathol (1986) 0.76
Serum antibodies against alcohol-treated rabbit hepatocytes in patients with alcoholic liver disease. Clin Exp Immunol (1985) 0.75
The cross-linking of proteins with glutaraldehyde and its use for the preparation of immunoadsorbents. Immunochemistry (1969) 14.31
Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med (1978) 3.28
Detection of a liver-membrane autoantibody in HBsAg-negative chronic active hepatitis. N Engl J Med (1976) 2.57
Histocompatibility antigens, autoantibodies, and immunoglobulins in alcoholic liver disease. Br Med J (1976) 1.91
Alcoholic hepatitis. Cell-mediated immunological response to alcoholic hyalin. Gastroenterology (1976) 1.78
Alcoholic hyalin antigen (AHAg) and antibody (AHAb) in alcoholic hepatitis. Gastroenterology (1977) 1.57
Cirrhosis in the alcoholic and its relation to the volume of alcohol abuse. Ann N Y Acad Sci (1975) 1.55
In vivo and in vitro binding of IgA to the plasma membrane of hepatocytes. Scand J Immunol (1978) 1.47
Lymphocyte transformation and alcoholic liver injury. Gastroenterology (1972) 1.42
Changing pattern of alcoholic liver disease in Great Britain: relation to sex and signs of autoimmunity. Br Med J (1977) 1.38
Demonstration of binding sites for IgG Fc and the third complement component (C3) on isolated hepatocytes. J Immunol (1976) 1.36
Sequential production of fatty liver, hepatitis, and cirrhosis in sub-human primates fed ethanol with adequate diets. Proc Natl Acad Sci U S A (1975) 1.29
HLA-B8, immunoglobulins, and antibody responses in alcohol-related liver disease. J Clin Pathol (1980) 1.28
Detection of circulating immune complexes in alcoholic liver disease. Clin Exp Immunol (1978) 1.21
Changes in the solubility of immunoglobulins after fluorescent labeling and its influence on immunofluorescent techniques. J Histochem Cytochem (1972) 1.14
Pathogenesis of alcohol-induced accumulation of protein in the liver. J Clin Invest (1977) 1.13
Studies on the pathogenesis of chronic inflammatory liver diseases. I. Membrane-fixed IgG on isolated hepatocytes from patients. Clin Exp Immunol (1975) 0.97
Relationship between membrane-bound immunoglobulin and viral antigens in liver cells from patients with hepatitis B virus infection. Gastroenterology (1979) 0.97
Alcoholic steatonecrosis. I. Relationship between severity of hepatic disease and presence of Mallory bodies in the liver. Gastroenterology (1971) 0.88
Liver membrane antibodies in alcoholic liver disease: 1. prevalence and immunoglobulin class. Gut (1982) 0.86
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology (1997) 5.53
Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med (1992) 5.48
Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. N Engl J Med (1993) 4.36
Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet (1992) 2.44
Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology (2000) 2.44
Anti-ganglioside antibodies in children with coeliac disease: correlation with gluten-free diet and neurological complications. Aliment Pharmacol Ther (2004) 2.18
Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet (1992) 2.13
Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients. Cancer (1995) 2.11
A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost (2010) 2.08
Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology (1980) 2.04
Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer (1994) 1.81
Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol (1998) 1.79
Natural history and prognostic factors for chronic hepatitis type B. Gut (1991) 1.75
Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP) Am J Gastroenterol (1998) 1.74
Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis (2007) 1.73
Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci (2000) 1.71
Hepatitis C virus infection in chronic hepatitis B virus carriers. J Infect Dis (1991) 1.69
Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. Am J Respir Crit Care Med (2000) 1.68
Chronic atrophic gastritis and Helicobacter pylori infection in primary biliary cirrhosis: a cross-sectional study with matching. Ital J Gastroenterol Hepatol (1997) 1.63
Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis. Gut (1982) 1.60
Premature ovarian failure in patients with autoimmune Addison's disease: clinical, genetic, and immunological evaluation. J Clin Endocrinol Metab (2011) 1.60
Early and advanced gastric cancer in the follow-up of moderate and severe gastric dysplasia patients. A prospective study. I.G.G.E.D.--Interdisciplinary Group on Gastric Epithelial Dysplasia. Endoscopy (1993) 1.58
Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med (2013) 1.57
Oxidative DNA damage accumulation in gastric carcinogenesis. Gut (1998) 1.57
A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology (1992) 1.52
Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. Scand J Gastroenterol (1997) 1.52
Immunoprecipitation assay for autoantibodies to steroid 21-hydroxylase in autoimmune adrenal diseases. Clin Chem (1995) 1.51
Spontaneous regression of hepatitis B virus-associated cirrhosis developed in childhood. Dig Liver Dis (2005) 1.51
Anti-heart and anti-intercalated disk autoantibodies: evidence for autoimmunity in idiopathic recurrent acute pericarditis. Heart (2010) 1.51
Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol (1992) 1.50
Prevalence of coeliac disease in primary biliary cirrhosis and of antimitochondrial antibodies in adult coeliac disease patients in Italy. Dig Liver Dis (2002) 1.50
Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. Aliment Pharmacol Ther (2006) 1.48
Autoimmune gastritis: histology phenotype and OLGA staging. Aliment Pharmacol Ther (2012) 1.48
Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study. J Rheumatol (2000) 1.48
Gross pathologic types of hepatocellular carcinoma in Italian patients. Relationship with demographic, environmental, and clinical factors. Cancer (1993) 1.46
p53 alteration in gastric precancerous lesions. Am J Pathol (1994) 1.45
The prevalence of oesophageal eosinophilia and eosinophilic oesophagitis: a prospective study in unselected patients presenting to endoscopy. Aliment Pharmacol Ther (2013) 1.45
bcl-2 and p53 immunophenotypes in pre-invasive, early and advanced oesophageal squamous cancer. Histopathology (1997) 1.43
Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha. J Hepatol (1994) 1.43
T-lymphocyte cytotoxicity to HBsAg-coated target cells in hepatitis b virus infection. Gut (1977) 1.42
Insulin autoantibodies as markers of potential diabetes mellitus. Lancet (1989) 1.40
Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol (1994) 1.40
Isolation of Helicobacter pylori from sheep-implications for transmission to humans. Am J Gastroenterol (2001) 1.40
High in vivo expression of interleukin-17 receptor in synovial endothelial cells and chondrocytes from arthritis patients. Rheumatology (Oxford) (2001) 1.40
Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis Rheum (1998) 1.39
Amoxycillin tolerance in Helicobacter pylori. J Antimicrob Chemother (1999) 1.38
Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology (1986) 1.38
Liver cell surface localization of hepatitis B antigen and of immunoglobulins in acute and chronic hepatitis and in liver cirrhosis. Clin Exp Immunol (1976) 1.35
Selective migration of the human helper-inducer memory T cell subset: confirmation by in vivo cellular kinetic studies. Eur J Immunol (1991) 1.34
Adjustment to concentration-dilution of spot urine samples: correlation between specific gravity and creatinine. Int Arch Occup Environ Health (2001) 1.31
Helicobacter pylori infection enhances mucosal interleukin-1 beta, interleukin-6, and the soluble receptor of interleukin-2. Int J Clin Lab Res (1996) 1.28
Fibrosis progression in initially mild chronic hepatitis C. J Viral Hepat (2006) 1.26
Differential distribution of hepatitis B core and E antigens in hepatocytes: analysis by monoclonal antibodies. Hepatology (1986) 1.26
Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology (1997) 1.24
Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol (2000) 1.24
Core antigen-specific immunoglobulin G bound to the liver cell membrane in chronic hepatitis B. Gastroenterology (1982) 1.24
Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther (2003) 1.23
Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis (1987) 1.23
Suppressor cell activity in viral and non-viral chronic active hepatitis. Clin Exp Immunol (1980) 1.23
Helicobacter pylori babA2, cagA, and s1 vacA genes work synergistically in causing intestinal metaplasia. J Clin Pathol (2003) 1.23
Loss of FHIT expression in gastric carcinoma. Cancer Res (1998) 1.23
Long-term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology (1988) 1.23
Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology (1990) 1.23
Helicobacter pylori virulence genes and host IL-1RN and IL-1beta genes interplay in favouring the development of peptic ulcer and intestinal metaplasia. Cytokine (2002) 1.20
Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Res (1996) 1.19
Autoimmune thrombocytopenia (AITP) and thyroid autoimmune disease (TAD): overlapping syndromes? Clin Exp Immunol (1998) 1.18
Origin of spurious multiple bands in the amplification of microsatellite sequences. Mol Pathol (1999) 1.18
Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch Intern Med (1994) 1.17
Chronic hepatitis C in children: the pathological and clinical spectrum. Gastroenterology (1998) 1.17
Fez1/lzts1 alterations in gastric carcinoma. Clin Cancer Res (2001) 1.17
Risk of type 1 diabetes development in children with incidental hyperglycemia: A multicenter Italian study. Diabetes Care (2001) 1.17
Definition of hepatitis B virus (HBV)-specific target antigens recognized by cytotoxic T cells in acute HBV infection. Clin Exp Immunol (1987) 1.16
Changes in hepatitis Be antigen/antibody system in children with chronic hepatitis B virus infection. J Pediatr (1983) 1.13
Ageing induces left ventricular concentric remodelling in normotensive subjects. J Hypertens (1995) 1.13
Clinical and subclinical organ-specific autoimmune manifestations in type 1 (insulin-dependent) diabetic patients and their first-degree relatives. Diabetologia (1984) 1.12
Auto-immune disorders in localized scleroderma. Arch Dermatol Res (1990) 1.12
Chemokine production by human chondrocytes. J Rheumatol (1999) 1.12
Prevalence of intestinal metaplasia in the distal oesophagus, oesophagogastric junction and gastric cardia in symptomatic patients in north-east Italy: a prospective, descriptive survey. The Italian Ulcer Study Group "GISU". Dig Liver Dis (2001) 1.11
Expression of intercellular adhesion molecule-1 (ICAM-1) on thyroid epithelial cells in Hashimoto's thyroiditis but not in Graves' disease or papillary thyroid cancer. Clin Exp Immunol (1991) 1.11
Common mutations in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients of different origins. Mol Endocrinol (1998) 1.11
Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices. Gastroenterology (1992) 1.10
Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer (1998) 1.10
Squamous cell carcinoma antigen in human liver carcinogenesis. J Clin Pathol (2007) 1.10
Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol (1997) 1.09
Influence of chronic alcohol abuse on body weight and energy metabolism: is excess ethanol consumption a risk factor for obesity or malnutrition? J Intern Med (1998) 1.09
Bone microarchitecture evaluated by histomorphometry. Micron (2005) 1.09
Letter: gastric cancer and pernicious anaemia--often Helicobacter pylori in disguise. Aliment Pharmacol Ther (2013) 1.08